Back to search

Article

BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)

2025-10-22

Abstract excerpt

Ovarian clear cell carcinoma (OCCC) is highly chemo-resistant and has worse clinical outcome at advanced stages than other ovarian cancer subtypes. The most frequent (∼50%) alterations in OCCC are AT-rich interactive domain 1A gene (ARID1A) mutations which lead to ARID1A deficiency. However, OCCC that retains ARID1A function differs substantially from ARID1A mutated OCCC. Particularly, targeted therapies that sens...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
65082eca-f4a0-586f-8a9a-f64f573ae33d
DOI
10.1101/2025.10.21.683700
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)DOI 10.1101/2025.10.21.683700
Select a neighboring publication to make it the new centre.